Human Endoglin / CD105 Protein, His Tag

Catalog # ENN-H52H9

Synonym

Endoglin,CD105,ENG,END

Source

Human BST1, His Tag (ENN-H52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 26 - Gly 586 (Accession # P17813-1).
Predicted N-terminus: Glu 26

Molecular Characterization

This protein carries a polyhistidine tag at the C-terminus.

The protein has a calculated MW of 62.6 kDa. The protein migrates as 80-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Endotoxin

Less than 1.0 EU per μg by the LAL method.

Purity

>95% as determined by SDS-PAGE.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.

Contact us for customized product form or formulation.

Reconstitution

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.

SDS-PAGE



Human BST1, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.

Background

Endoglin (ENG), endothelial glycoprotein, also known as CD105, is a coreceptor of the transforming growth factor-β (TGFβ) family signaling complex, which is highly expressed on endothelial cells and plays a key role in angiogenesis. It regulates the responses associated with binding to transforming growth factor β1 egg (Activin-A), bone morphogenetic protein 2 (BMP-2), and bone morphogenetic protein 7 (BMP-7). Endoglin may be involved in autosomal dominant disease, such as hereditary hemorrhagic telangiectasia 1 (HHT1). Circulating soluble ENG is also elevated in pulmonary arterial hypertension(PAH) and is proposed to be a biomarker for the prognosis of group I PAH patients.

Clinical and Translational Updates

Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.